Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

N<sup>6</sup>-Methyladenosine on Key Messenger RNAs Governs Reproductive Development and Metabolic Adaptation in Human Blood Fluke.

Research (Washington, D.C.)·2026
Same author

N-Homocysteinylation of Cofilin-1 Aggravates Epileptic Pathophysiology via Disruption of Actin Dynamics.

Neuroscience bulletin·2026
Same author

Clinically translatable ultrasound localization microscopy reveals cerebrovascular remodelling and prognosis in patients with traumatic brain injury.

Nature biomedical engineering·2026
Same author

Fast but faulty: Poor sleep skews intuitive-reflective balance in emergency decision-making.

Ergonomics·2026
Same author

Large Artery occlusion Treated in Extended Time with Mechanical Thrombectomy (LATE-MT): Protocol for a multicenter randomized clinical trial.

International journal of stroke : official journal of the International Stroke Society·2026
Same author

Why are iron chelators not as effective as artemisinin in killing malaria parasites?

Parasites & vectors·2026

Related Experiment Video

Updated: Jul 13, 2026

Cost-Efficient Transcriptomic-Based Drug Screening
06:40

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

Single-nucleus transcriptomics-based drug screening platform for focal cortical dysplasia.

Chuantao Fang1,2,3, Guilin Meng4, Lin Yang5

  • 1Center for Clinical Research and Translational Medicine, Department of Neurosurgery, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China.

Molecular Psychiatry
|July 11, 2026
PubMed
Summary

Researchers identified molecular changes in brain cells, particularly vascular cells, in focal cortical dysplasias (FCDs). This led to the discovery of four compounds that show promise in reducing seizure activity in epilepsy models.

More Related Videos

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Related Experiment Videos

Last Updated: Jul 13, 2026

Cost-Efficient Transcriptomic-Based Drug Screening
06:40

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Area of Science:

  • Neuroscience
  • Genomics
  • Pharmacology

Background:

  • Focal cortical dysplasias (FCDs) are a primary cause of drug-resistant epilepsy.
  • The molecular complexity of FCDs hinders the development of effective antiseizure drugs.

Purpose of the Study:

  • To investigate the transcriptional landscape of human FCDs.
  • To identify potential therapeutic targets and compounds for treating refractory epilepsy.

Main Methods:

  • Single-nucleus RNA sequencing was performed on 49 human neocortical specimens (FCD I-III).
  • Transcriptional signatures were integrated with the Connectivity Map to prioritize drug candidates.
  • In vivo efficacy of candidate compounds was assessed in epilepsy models.

Main Results:

  • Significant transcriptional alterations were observed in non-neuronal cells (astrocytes, vascular cells), indicating dysfunction.
  • Vascular-associated signatures were a common feature across FCD subtypes.
  • Four compounds (Betamethasone, Lodamin, Valproxam, Licochalcone A) demonstrated reduced seizure-like activity in vivo.

Conclusions:

  • A multicellular, transcriptome-guided framework can link disease signatures to therapeutic strategies for refractory epilepsy.
  • The study highlights vascular cell dysfunction as a convergent feature in FCDs.
  • Identified compounds offer potential avenues for novel antiseizure medication development.